skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting

Clinical ophthalmology (Auckland, N.Z.), 2023-01, Vol.17, p.1129-1135 [Peer Reviewed Journal]

2023 Munayco-Guillén et al. ;COPYRIGHT 2023 Dove Medical Press Limited ;2023 Munayco-Guillén et al. 2023 Munayco-Guillén et al. ;ISSN: 1177-5467 ;ISSN: 1177-5483 ;EISSN: 1177-5483 ;DOI: 10.2147/OPTH.S398359 ;PMID: 37077223

Full text available

Citations Cited by
  • Title:
    Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting
  • Author: Munayco-Guillén, Fernando ; Vazquez-Membrillo, Miguel Angel ; Garcia-Roa, Marlon Rafael ; De La Cruz-Vargas, Jhony Alberto ; García-Perdomo, Herney Andrés ; Pichardo-Rodriguez, Rafael
  • Subjects: antiangiogenic diabetes mellitus intravitreal injection macular edema optical coherence tomography ziv-aflibercept ; Care and treatment ; Diabetes therapy ; Dropsy ; Edema ; Medical research ; Medicine, Experimental ; Original Research ; Type 2 diabetes
  • Is Part Of: Clinical ophthalmology (Auckland, N.Z.), 2023-01, Vol.17, p.1129-1135
  • Description: It has been reported that intravitreal Ziv-aflibercept is a safe and effective drug for the treatment of diabetes macular edema (DME). The objective of this study was to evaluate in a real-life setting, the efficacy of intravitreal Ziv-aflibercept in the treatment of DME after the administration of three consecutive monthly doses. A single arm, prospective cohort study. We included patients with DME who received three doses of intravitreal Ziv-aflibercept. Data such as best corrected visual acuity (BCVA) and tomographic biomarkers before treatment and a month after the third dose were collected. DME was staged using the Panozzo classification. Thirty-eight patients participated for a total of 53 eyes. The mean age was 59 ± 8.1 years. We observed significant changes after the third dose in the parameters studied (BCVA in LogMAR pre-treatment (0.6 ± 0.33) and post-treatment (0.4 ± 0.29) [p<0.001], macular thickness pre-treatment (501 ± 167 µm) and post-treatment (324 ± 114 µm) [p<0.001], macular volume pre-treatment 10.8 (7.5-17.8) mm and post-treatment 9.3 (0-13.6) mm [p<0.005]). And 73.6% of the patients presented an advanced severe stage during their pre-treatment evaluation and after post-treatment, 64.2% of the patients no longer presented edema. No systemic or ocular adverse events occurred. The use of three consecutive monthly doses of intravitreal Ziv-aflibercept in a real-life setting is effective and safe in the management of diabetic macular edema.
  • Publisher: New Zealand: Dove Medical Press Limited
  • Language: English
  • Identifier: ISSN: 1177-5467
    ISSN: 1177-5483
    EISSN: 1177-5483
    DOI: 10.2147/OPTH.S398359
    PMID: 37077223
  • Source: GFMER Free Medical Journals
    PubMed Central
    DOVE Medical Press Journals
    ProQuest Central
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait